Literature DB >> 9708609

Colonization with vancomycin-resistant enterococci in chronic hemodialysis patients.

M C Roghmann1, J C Fink, L Polish, T Maker, J Brewrink, J G Morris, P D Light.   

Abstract

Vancomycin-resistant enterococcus (VRE) has been identified with increased frequency in dialysis populations, but the risk factors for VRE colonization are not well defined in hemodialysis patients. Patients from a university-affiliated outpatient dialysis center had surveillance stool or rectal cultures for VRE during April 1994 and January 1996. The combined cohort of 168 patients was followed-up for all-cause mortality, subsequent hospitalization, and VRE infection. Demographic and risk factor information, including age, gender, race, diabetes, coronary artery disease (CAD), and human immunodeficiency virus (HIV) infection, were collected on all patients. Sixteen patients had surveillance cultures grow vancomycin-resistant Enterococcus faecium or E faecalis (VREF), and nine additional patients had clinical cultures positive for VREF. The median follow-up time for patients with positive surveillance or clinical cultures for VREF was 421 days versus 423 days for those without VREF. Patients with positive surveillance cultures for VREF had less time on hemodialysis before screening (median = 207 days v 822 days; P < 0.01), and more hospitalization in the year before screening (median = 19 days v 3 days, P < 0.01) compared with those without VREF. Patients with VREF colonization were more likely to develop infection with VREF (25% v 1%, P < 0.01) than those without VREF colonization. However, adjusting for age, diabetes, coronary artery disease, and acquired immune deficiency syndrome (AIDS) using Cox-proportional hazards models, the presence of VREF on screening culture was not associated with increased risk of death (RR = 1.1, P = 0.86). Thus after adjusting for other comorbidities, VREF colonization was not associated with increased mortality. Patients with end-stage renal disease (ESRD) on hemodialysis who are hospitalized are more likely to have VREF, but longer duration on hemodialysis was not associated with presence of this organism. This suggests that VRE transmission occurs predominantly in the inpatient setting.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708609     DOI: 10.1053/ajkd.1998.v32.pm9708609

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

1.  Successful treatment of vancomycin-resistant enterococcus peritonitis using linezolid without catheter removal in a peritoneal dialysis patient.

Authors:  In Ji Song; Ji Won Seo; Young Eun Kwon; Young Ly Kim; Tae Seop Lim; Ea Wha Kang; Tae Ik Chang
Journal:  Perit Dial Int       Date:  2014 Mar-Apr       Impact factor: 1.756

2.  Risk factors for new detection of vancomycin-resistant enterococci in acute-care hospitals that employ strict infection control procedures.

Authors:  Alexander A Padiglione; Rory Wolfe; Elizabeth A Grabsch; Di Olden; Stephen Pearson; Clare Franklin; Denis Spelman; Barrie Mayall; Paul D R Johnson; M Lindsay Grayson
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

3.  Multidrug-resistant gram-negative bacteria among patients who require chronic hemodialysis.

Authors:  Aurora Pop-Vicas; James Strom; Karen Stanley; Erika M C D'Agata
Journal:  Clin J Am Soc Nephrol       Date:  2008-03-05       Impact factor: 8.237

Review 4.  Prevalence of vancomycin resistance among isolates of enterococci in Iran: a systematic review and meta-analysis.

Authors:  Abbas Moghimbeigi; Meisam Moghimbeygi; Majid Dousti; Faezeh Kiani; Fatemeh Sayehmiri; Nourkhoda Sadeghifard; Ali Nazari
Journal:  Adolesc Health Med Ther       Date:  2018-11-15

5.  Factors associated with acquisition of glycopeptide-resistant enterococci during a single-strain outbreak.

Authors:  S Deboscker; P Schneider; F Séverac; C Ménard; J Gaudart; T Lavigne; N Meyer
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

6.  Vancomycin-Resistant Entrococci colonization in chronic hemodialysis patients and its risk factors in southern Iran (2005-2006).

Authors:  S Shaghaghian; B Pourabbas; A Alborzi; M Askarian; J Mardaneh
Journal:  Iran Red Crescent Med J       Date:  2012-10-30       Impact factor: 0.611

7.  Prevalence of vancomycin-resistant enterococci colonization and its risk factors in chronic hemodialysis patients in Shiraz, Iran.

Authors:  Ojan Assadian; Mehrdad Askarian; Maria Stadler; Soheila Shaghaghian
Journal:  BMC Infect Dis       Date:  2007-06-06       Impact factor: 3.090

8.  Healthcare-associated vancomycin resistant Enterococcus faecium infections in the Mansoura University Hospitals intensive care units, Egypt.

Authors:  Dalia Moemen; Doaa Tawfeek; Wafaa Badawy
Journal:  Braz J Microbiol       Date:  2015-07-01       Impact factor: 2.476

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.